Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice
The concept of fitness for novel agents in chronic lymphocytic leukemia (CLL) remains debated. Comorbidities and treatment-related logistics are increasingly recognized as key factors in treatment feasibility. Venetoclax-obinutuzumab (VO) has demonstrated efficacy in both fit and unfit patients in...
Saved in:
Similar Items
-
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort
by: Andrea Serafin, et al.
Published: (2025-07-01) -
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma
by: Caterina Musolino, et al.
Published: (2017-01-01) -
BING-NEEL SYNDROME: ILLUSTRATIVE CASES AND COMPREHENSIVE REVIEW OF THE LITERATURE
by: Marzia Varettoni, et al.
Published: (2017-10-01) -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: AnnaMaria Nosari
Published: (2012-11-01) -
Clinical significance of preoperative nutrition and inflammation assessment tools in gastrointestinal cancer patients undergoing surgery: a retrospective cohort study
by: Valentina Casalone, et al.
Published: (2025-05-01)